The allergy diagnostics market is expected to register a CAGR of 11.3% during the forecast period.
Several research studies found that patients with asthma are at a higher risk of viral infections such as COVID-19. The Coronavirus can cause severe acute respiratory syndrome and infect the lower and upper airway tract, thus creating a critical clinical issue for asthmatic patients.
Furthermore, according to a research study by Vincenzo Patella et al., published in Clinical and Molecular Allergy October 2020, in Italy, during the COVID-19 pandemic 2020, doctors experienced difficulties treating chronic diseases for most patients. Moreover, most allergy/immunology care was delayed or postponed, or handled through virtual care. For patients with asthma of a certain severity, there was a limited provision for face-to-face visits under critical conditions.
Allergic rhinitis or hay fever is a global health problem characterized by symptoms that include itching, nasal congestion, sneezing, and rhinorrhea. According to a research study by Desiderio Passali et al., published in Asia Pacific Allergy Journal January 2018, globally, the prevalence of allergic rhinitis was 15%-25%. Children, adolescents, and young adults were the most affected by allergic rhinitis with comorbidities of asthma, sinusitis, conjunctivitis, and nasal polyposis.
Food allergy is a growing health concern, with increasing prevalence in both developed and developing countries. According to a research study by Wenyin Loh et al., published in the International Journal of Environmental Research and Public Health, September 2018, in developed countries, food allergy has been reported to be as high as 10%, with the most prevalence witnessed among younger children. Moreover, there is an increasing prevalence of food allergies in developing countries; China and Africa are similar to developed countries in terms of the prevalence of allergies.
Therefore, with the growing burden of allergic diseases, the new diagnostic market for the same is expected to grow significantly. Furthermore, the latest diagnostic strategies for allergies and research on new treatment approaches are expected to drive the market studied over the forecast period. However, a lack of awareness about allergic diseases and affordability of allergy diagnostics are expected to restrain the market growth.
Key Market Trends
Inhaled Allergens Segment is expected to hold Major Market Share Over the Forecast Period
Depending on how they 'invade' a body, allergens can be classified into consumed allergens, ingested allergens, contact allergens (physical contact), and inhaled allergens. Of these, the inhaled allergens hold the largest share of the market, as they are the most common among all the allergens.
Globally, viral infection is a major triggering factor for allergic diseases and asthma. Worldwide, the COVID-19 has challenged the healthcare system's capacities, reshaping doctor-patient interaction with telemedicine. According to a research study by Adriana Izquierdo-Dominguez et al., published in Current Allergy and Asthma Reports February 2021, the outbreak of COVID-19 in 2020 made it difficult to prioritize patients with allergic diseases (AD). Since COVID-19 shares many symptoms with AD, face-to-face evaluation with a patient suffering from the latter has become a problem.
Inhaled allergens affect the body when they come in contact with the membranes of the nostrils, throat, or lungs. Pollen is the most common inhaled allergen. Ingested allergens are present in certain foods, such as soy, peanuts, and seafood.
The most common allergy symptoms caused by inhaled allergens are itchy eyes, sneezing, watery eyes, etc. The rising pollution in the environment, coupled with the changing lifestyle of the people, is boosting the segment's growth.
The University of South Carolina is working on several inhaled allergens. For instance, it conducted a study on dust mite allergens, which are believed to be among the most potent triggers of asthma. Most mite allergic patients (80%) have IgE antibodies against the mite allergens. These allergens are cysteine proteases, and their proteolytic activity contributes significantly to allergenicity.
The market players adopt various strategies such as product launches, collaborations, acquisitions, and expansions to increase market share. For instance, in December 2018, Hycor Biomedical Inc. received United States Food and Drug Administration's (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.
On the other hand, food allergens are expected to witness the fastest growth rate, owing to considerable unawareness among individuals regarding certain food allergies. Thus, the above mentioned factors are expected to drive market growth over the forecast period.
North America dominates the Market and is expected to do the Same over the Forecast Period
Some of the factors that are driving the market growth include increasing incidences of allergic diseases, environmental pollution, and the presence of key market players in the region.
In the North American region, there was a huge impact of COVID-19 on allergist practices such as diagnosis of allergy diseases and have adapted to state-wide limitations in non-essential medical visits and testing and to the mitigation of the risk of disease transmission to providers, staff, and patients. Moreover, the Centers for Disease Control and Prevention (CDC) has issued many guidelines for healthcare providers, which include the use of appropriate personal protective equipment (PPE) and the evaluation and testing of patients suspected of being infected with COVID-19. It has become more important than ever to recognize the differences between allergies, infection with COVID-19, and other common upper respiratory diseases.
Asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada's 2019 annual asthma survey report. Due to the high incidence of asthma in Canada, it is expected to increase demand for allergy diagnostics procedures in near future.
Moreover, as per the Global Asthma Network 2018 report, the economic burden of asthma has been increased in the United States i.e., total annual asthma costs in the United States increased from USD 60 billion in 2002 to USD 64 billion in 2011. In 2018, annual direct costs per patient in the United States were more than USD 3,000. Due to high death rates associated with asthma and increasing investment in asthma in this country the market is expected to show significant growth in the future.
According to a research study by Segura, L. R., et al., published in International Nut and Dried Fruit Council 2020, the overall positivity of food allergy to at least one food among the Brazilian population was 24%. Moreover, positivity for foods was more frequent across different age groups in young children (less than 5 years) with milk, and in older children (6-17 years) food allergy was shown with peanut, almond, wheat, soy, and maize.
There are several factors that make the United States the largest market for allergy diagnostics, such as high awareness toward allergies among the population, better regulatory guidelines that mandate allergic testing in all cases of intensive and emergency care, and better healthcare infrastructure to deal with patient's allergic situations. Thus, considering above mentioned factors it is expected to fuel the market growth in the North American region over the forecast period.
The allergy diagnostics market is fragmented, competitive, and consists of several market players. The presence of major market players, such as BioMerieux SA, Thermo Fischer Scientific Inc, Omega Diagnostics, Siemens Healthineers AG, Hitachi Chemical Diagnostics Inc., and Danaher Corporation, intensifies the market competition. The increasing innovation and investment by various public and private organizations are expected to intensify the industry rivalry worldwide.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Incidences of Allergic Diseases
- 4.2.2 Environmental Pollution
- 4.3 Market Restraints
- 4.3.1 Lack of Awareness About Allergic Diseases
- 4.3.2 Affordability of Allergy Diagnostics
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Allergen
- 5.1.1 Inhaled Allergens
- 5.1.2 Food Allergens
- 5.1.3 Other Allergens
- 5.2 By Product
- 5.2.1 Instruments
- 5.2.2 Consumables
- 5.2.3 Luminometers
- 5.3 By End User
- 5.3.1 Diagnostic Laboratories
- 5.3.2 Hospitals
- 5.3.3 Other End Users
- 5.4 Geography
- 5.4.1 North America
- 184.108.40.206 United States
- 220.127.116.11 Canada
- 18.104.22.168 Mexico
- 5.4.2 Europe
- 22.214.171.124 Germany
- 126.96.36.199 United Kingdom
- 188.8.131.52 France
- 184.108.40.206 Italy
- 220.127.116.11 Spain
- 18.104.22.168 Rest of Europe
- 5.4.3 Asia-Pacific
- 22.214.171.124 China
- 126.96.36.199 Japan
- 188.8.131.52 India
- 184.108.40.206 Australia
- 220.127.116.11 South Korea
- 18.104.22.168 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 22.214.171.124 GCC
- 126.96.36.199 South Africa
- 188.8.131.52 Rest of Middle East and Africa
- 5.4.5 South America
- 184.108.40.206 Brazil
- 220.127.116.11 Argentina
- 18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 BioMerieux SA
- 6.1.2 Danaher Corporation
- 6.1.3 Showa Denko Materials Co., Ltd. (Hitachi Chemical Diagnostics)
- 6.1.4 HOB Biotech Group Corp. Ltd
- 6.1.5 HYCOR Biomedical
- 6.1.6 Lincoln Diagnostics Inc.
- 6.1.7 Omega Diagnostics Group Plc
- 6.1.8 Siemens Healthineers AG
- 6.1.9 Stallergenes Greer Ltd
- 6.1.10 Thermo Fischer Scientific Inc
- 6.1.11 PerkinElmer Inc. (Euroimmun AG )
- 6.1.12 R-Biopharm AG
- 6.1.13 Immunodiagnostic Systems Holdings PLC (IDS)
- 6.1.14 Biomerica, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS